๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of Parkinson's Disease with Ropinirole after Pergolide-Induced Retroperitoneal Fibrosis

โœ Scribed by Dr. Brian C. Lund; Dr. Richard F. Neiman; Dr. Paul J. Perry


Book ID
115047654
Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
22 KB
Volume
19
Category
Article
ISSN
0277-0008

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Early treatment benefits of ropinirole p
โœ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 488 KB ๐Ÿ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn

Sumanirole versus placebo or ropinirole
โœ Paolo Barone; Janice Lamb; Amanda Ellis; Zoe Clarke ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 171 KB

## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib

A comparison of sumanirole versus placeb
โœ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 146 KB ๐Ÿ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.